Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAB014 vs ranibizumab in neovascular age-related macular degeneration
CTR20211015Phase 3Completed
- Sponsor
- TOT Biopharm
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in exudative macular degeneration, sponsored by TOT Biopharm. Started May 2021; status: completed.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20211015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211015.